The marketing authorisation for Removab has been withdrawn at the request of the marketing authorisation holder.
Removab : EPAR - Summary for the public (PDF/487.7 KB)
First published: 12/05/2009
Last updated: 12/07/2017
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Neovii Biotech GmbH
|Date of issue of marketing authorisation valid throughout the European Union||
02/06/2017 Removab - EMEA/H/C/000972 - IAIN/0020
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Removab is indicated for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.